Request an Appointment

In the Department of Hematology of Hadassah University Hospital, innovative drugs for chemotherapy, immunotherapy and biotherapy are applied. The department’s treatment success rates are among the highest in the country.

When it comes to the treatment of hematopoietic system cancer by bone marrow transplantation, Hadassah ranks first in Israel.

Up to 80% of patients diagnosed with lymphoma and up to 95% of leukemia patients are completely cured here (the percentage of success depends on the type of tumor). This is a very high rate, one of the best in the Middle East and Europe


The main types of diseases that are successfully diagnosed and treated in the
Department of Hematology:

different types of leukemia ;
different types of lymphomas ;
blood clotting disorders and hereditary blood diseases;
thrombocytopenia (low level of platelets in the blood);
violation of the hemostasis system;
lymphoproliferative conditions

The Hematology department combines all the elements that achieve accurate diagnose and high level treatment results, such as:

The medical staff  consists of leading hematologists in Israel.
Innovative drugs
Modern diagnostic methods based on molecular biology and immunofluorescence.


Hadassah is a leader in clinical research in the field of oncologic hematology

Hadassah constantly conducts research on the latest drugs developed by researchers of the Department of Hematology. Patients for whom due to their advanced disease condition the protocols of treatment cannot be recommended as a therapy option, even the most innovative ones, are invited to participate in research programs. This gives them a chance and doctors achieve excellent results.
Drugs are provided to patients free of charge, trial participants pay only for concomitant diagnostics.

The latest immunotherapy drugs in oncologic hematology

In the treatment of myeloma and various types of lymphomas, oncologic hematologists of the Hadassah Hospital use the latest generation of immunotherapy drugs, such as:

  • proteasome inhibitors that block the creation of a cell-destroying protein.
  • immunomodulators that do not directly affect the tumor, but cause an immune response of cells.
  • monoclonal antibodies (elotuzumab, daratumumab, isatuximab) that bind to cell-destroying proteins and cause an immune system response.

Doctors achieve the greatest effect with an individually selected combination of drugs for each patient.





The first delegation of our partners from Abu Dhabi


Medical director of Health Plus UAE in Conference Arab Health 2021, Dubai


Participation in the 5th Global Healthcare Travel Forum I Kyiv, Ukraine